Prenetics Global Limited (NASDAQ: PRE) announced record-breaking financial results for the fourth quarter and full fiscal year ended December 31, 2025. The company reported a massive 480% year-over-year increase in revenue, highlighting a period of exceptional operational expansion. A primary driver of this growth was the IM8 health and longevity brand, which achieved $120 million in Annual Recurring Revenue (ARR) within just 12 months of its launch. These results reflect rapid market adoption and the successful scaling of the company's premium health and wellness offerings. Management's strategic focus on high-growth segments has positioned Prenetics as a significant player in the health sciences sector. Investors are closely monitoring the stock as these figures underscore a strong financial trajectory and robust operational efficiency heading into 2026.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis